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Abstract 
Preeclampsia is a pregnancy-specific condition affecting 2-7% of women and a leading cause 
of perinatal and maternal morbidity and mortality. Preeclampsia may also predispose the fetus 
to increased risks of adult cardiovascular disease. Selenium, acting through the selenoprotein 
glutathione peroxidases, has critical roles in regulating antioxidant status. Recent reports 
implicate poor maternal selenium status as a nutritional factor predisposing the mother to 
preeclampsia but the fetus and placenta have not been studied in tandem. Measurement of 
selenium concentrations, expression and activity levels of glutathione peroxidase and markers 
of oxidative stress were performed on maternal and umbilical venous blood samples or the 
placenta from 27 normal pregnant, 25 preeclamptic and 22 healthy age-matched non-pregnant 
women. The results of this study revealed highly significant reductions in serum selenium 
concentrations and plasma glutathione peroxidase activity in pregnancy per se compared to 
non-pregnant controls. Moreover, these levels were further decreased in the preeclamptic 
mothers and babies compared to normal pregnancies. Umbilical venous selenium was 
particularly low (42.1±11.8 and 29.0 ± 9.9 g/L; mean ±s.d.; P<0.05). Both mother and baby 
had significantly increased levels of markers for oxidative stress in the preeclamptic group. 
The placental glutathione peroxidase activity and immunohistochemical staining were also 
reduced in the preeclampsia placentae. Oxidative stress associated with preeclampsia may be 
a consequence of reduced antioxidant defence pathways specifically involving glutathione 
peroxidases, perhaps linked to reduced selenium availability. Reduced glutathione 
peroxidases could be associated with increased generation of toxic lipid peroxides 
contributing to the endothelial dysfunction and hypertension of preeclampsia. 
 
Key Words: pregnancy, human; preeclampsia; hypertension; oxidative stress; selenium; 
glutathione peroxidase; placenta. 
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Introduction 
Preeclampsia is estimated to occur in 2-7% of all pregnancies and is a leading cause of 
maternal and perinatal mortality and morbidity in the Western world1; together with other 
hypertensive disorders of pregnancy it is responsible for approximately 60,000 deaths each 
year2. Moreover, the effects of the disease are not restricted to pregnancy as it also 
predisposes both the mother and baby to adult cardiovascular disease3. Preeclampsia is now 
commonly regarded as being a state of oxidative stress, thought to arise from a biochemical 
imbalance which occurs from excessive generation of free radical formation and/or 
inadequate antioxidant capacity (see: 4). It is thought that excessive production of reactive 
oxygen species (ROS), resulting in oxidative stress secondary to reduced placental perfusion 
plays a critical role as a possible mediator of endothelial cell dysfunction5, hypertension and 
thus clinical manifestations of preeclampsia6.   
 
The trace element selenium is an essential component of the antioxidant selenoproteins, 
including glutathione peroxidases (GPx). These remove the products of attack by ROS 
(hydroperoxides and oxidized lipoproteins) which can break down to further reactive free 
radicals and cytotoxic agents7, and so limit adverse effects on the endothelium8.  Various 
forms of GPx are found in vertebrates: the cellular and cytosolic GPx (GPx1), the cytosolic 
gastrointestinal GPx (GPx2), the extracellular plasma GPx (GPx3) and the phospholipid 
hydroperoxide GPx (GPx4)9.  Two studies have shown decreases in maternal serum or toenail 
selenium concentrations in preeclamptic patients compared to normal pregnant controls10, 11 
and other studies have reported significant reductions in maternal plasma12 and placental13, 14 
GPx activities in preeclamptic patients.  We are not aware of any studies linking selenium and 
GPx in the mother, placenta and baby.  We hypothesized that fetal selenium and GPx 
concentrations would also be reduced in preeclamptic pregnancy, which could contribute to 
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present morbidity and future cardiovascular risk. We have therefore conducted a cross-
sectional study to explore these factors in tandem comparing patients and their babies from 
normal and preeclamptic pregnancies and, when appropriate, non-pregnant controls. 
 
Methods 
Power calculations: We calculated that a sample of 25 normal pregnant and 25 preeclamptic 
women would give us a 95% power of detecting a 30% difference in serum selenium 
concentration. 
 
Subjects: The study population consisted of three groups of Caucasian women: 27 normal, 25 
preeclamptic and 22 healthy age-matched women.  The investigations were approved by the 
Hospital Ethics Committee of the Queen’s Medical Centre, Nottingham and written, informed 
consent was obtained from each participant.  Cases were defined on admission with a clinical 
diagnosis of preeclampsia, defined as a systolic blood pressure of ≥ 140 mm Hg and diastolic 
pressure (Korokoff V) of ≥ 90 mm Hg on 2 occasions after 20 weeks gestation in a previously 
normotensive women and proteinuria > 300 mg/L, 500 mg/day or 2+ on dipstick analysis of 
midstream urine (MSU) if 24-hour collection result was not available.  Medical and obstetric 
histories, including delivery data, were obtained for each woman. The birthweight centile for 
each baby was computed, correcting for gestation age, sex, maternal parity and body mass 
index (BMI)15.  
 
Sample collection: Venous blood samples were collected in chilled tubes containing 
ethylenediaminetetraacetic acid (EDTA; GPx assays), heparin (thiobarbituric acid reactive 
substances (TBARS) assay) and plain tubes for serum (selenium assays) from both maternal 
and, where possible, umbilical cord before delivery and immediately after respectively.  
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Plasma and serum were stored at -80oC until biochemical analysis were performed.  In 
addition placental tissue samples were collected from three standardized locations between 
cord insertion and placental border; one set were snap frozen and stored at -80oC.  Another set 
were formalin fixed and wax-embedded for immunohistochemical analysis. 
 
Tissue preparation: Placental tissue fragments (100 mg) were thawed and homogenized in 3 
volumes of RIPA buffer (1 x PBS (pH 7.4), 0.1 % SDS, 1 % Igepal CA-630 (Sigma-Aldrich, 
Poole, UK) and 0.5% Sodium Deoxycholate) using an Ultra Turrax homogenizer.  Samples 
were centrifuged (3000 g, 10 mins, 4oC) and supernatants were stored at -80oC.  Protein 
concentrations were determined using the Lowry method16. 
 
Biochemical measurements: The plasma concentration of TBARS (a global measure of lipid 
peroxidation) was measured by the method of Urchiyama and Milhara17.  Samples were 
assayed in duplicate; the within- and between-assay coefficients of variation were 4% and 5% 
respectively 
 
Serum selenium concentrations were determined by a Varian SpectrAA graphite furnace 
atomic absorption spectrophotometer18.  Standard reference samples (Seronorm and serum 
control; purchased from Nycomed Pharma AS, Norway and UTAK trace element control, 
normal level) were used.  The intra- and inter-assay coefficients of variances were < 5% for 
both.  
 
mRNA expression measurements: Total RNA was extracted from a known amount of 
placental tissue (between 50 – 100 mg) using Tri-Reagent (Sigma-Aldrich, Poole, UK).  
Following RNA extraction, 1 µg of each samples was reverse transcribed in a 20 µl reaction 
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buffer (250 mM Tris.HCl, 40 mM KCl, 5 mM dithioerythritol pH 8.5), 2 mMdNTPs, 1 x 
hexanucleotide mix, 10 units RNase inhibitor, 10  units Reverse transcriptase (RT) (Roche 
Diagnostics, Lewes, UK) in a Touchgene Gradient thermocycler (Techne, Barloworld 
Scientific Ltd, Stone, UK). The conditions used to generate first strand cDNA were 72°C (5 
min), 4°C (2 min), 25°C (5 min), 25°C (10 min), 42°C (60 min), and 72°C (10 min).  RNA 
concentration and quality were verified by gel electrophoresis and spectrophotometrically; all 
samples had an A260/A280 ratio greater than 1.96 and were stored at −20°C. 
 
Standards for GPx 1, 2, 3, 4, and for the housekeeping gene 18s ribosomal RNA were made 
from cDNA obtained from a randomly selected control placental sample using semi-
quantitative polymerase chain reaction (PCR). The method used oligonucleotide primers to 
GPx 1, 2, 3, 4, and 18s genes generating specific intron-spanning products (Table 1). The 
PCR program comprised an initial denaturation stage (95°C, 15 min), amplification (stage I, 
94°C (30 s); stage II, annealing temperature (60oC, 30 s); stage III, 72°C (1 min), and final 
extension (72°C, 7 min; 8°C ‘hold’). The PCR mixture (final volume 20 μl) contained 7 μl 
nuclease-free water (Ambion), 10 μl thermo-start PCR master mix (ABgene, Epsom, UK)), 1 
μl forward primer, 1 μl reverse primer, and 1 μl RT (cDNA) product. The annealing 
temperature (60oC) and cycle number of all primers were optimized and used in their linear 
range.  The resultant PCR product was extracted after agarose gel electrophoresis (QIAquick 
gel extraction kit, Qiagen®, cat no. 28704), sequenced, and results cross-referenced against 
the Genbank website to determine specificity of the target gene.  Extracted PCR products 
were resuspended in nuclease-free water and a 10-fold serial dilution performed. Standards 
were stored at −20°C until use in quantitative PCR. 
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Quantitative PCR was used to examine the expression of GPx 1, 2, 3, 4, and 18s. PCR 
reactions, set up in duplicate, were carried out in 20 μl volumes consisting of 1 × SYBR® 
PCR mastermix (with ROX passive reference dye) (Qiagen Ltd, Crawley, UK), 500 nM 
forward primer, 500 nM reverse primer, and 7 μl nuclease-free water. Real time PCR was 
performed in a Techne Quantica™ 14 real-time thermocycler (Techne, Barloworld Scientific 
Ltd) on all samples at 95°C (15 min) followed by 45 cycles of 95°C (15 s), annealing 
temperature at 60oC (25 s), 72°C (25 s). Three negative control reactions were carried out 
with each set of samples analyzed: (1) no RNA template but RT and polymerase provided; (2) 
RNA and polymerase provided but no RT; and (3) RNA and RT provided but no polymerase. 
 
GPx activity assay: GPx activity was determined by a modified method of Paglia and 
Valentine19 in both plasma and placental extracts.  Activity was measured 
spectrophotometrically in duplicate by coupling the oxidation of glutathione and nicotinamide 
adenine dinucleotide phosphate (NADPH) using glutathione reductase.  Briefly, 900 μl of 
assay mix containing 0.1 M potassium phosphate, pH 7.0; 2 mM EDTA; 0.5 U/ml glutathione 
reductase; 10 mM glutathione and 0.3 mM reduced NADPH was placed into a WPA Biotech 
spectrophotometer set at 340 nm. Diluted tissue extracts or plasma (50 μl of 1/10 dilution) 
were added to the cuvette along with 50 μl of 20 mM tert-butyl hydroperoxide, a suitable 
substrate for GPx. The decrease in A340 was determined over a 3-min period and rate 
calculations were performed. GPx activity was standardised against protein concentrations 
and expressed as mmol/min/mg protein or mmol/min/ml for plasma samples; the inter- and 
intra-assay variations were < 5%. 
 
Histological analysis: Serial sections of 5μm were cut in the same orientation from paraffin-
embedded tissue blocks (Sledge Microtome, Anglia Scientific, Norwich, UK) and mounted 
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onto Superfrost plus glass microscope slides (Menzel-Glaser, Braunschweig, Germany). 
Before use, sections were dewaxed by immersion in xylene followed by rehydration in 
descending concentrations of alcohol (3 min each). 
 
Immunohistochemistry: Immunohistochemical analysis was performed using the Dako 
Envision™ visualization system (Dako, Ely, UK).  All GPx antibodies were purchased from 
Autogen Bioclear; Table 2 provides further details on antibody dilutions and positive controls.  
Antibodies to cytokeratin (CK-7) and CD-68 (Santa Cruz Biotechnology, Calne, UK) were 
used to confirm positive GPx staining in cytotrophoblast and Hofbauer cells respectively 
(Table 2).  A negative control was performed for each test section by omitting incubation in 
the primary antibody.  Sections were dehydrated in ascending concentrations of alcohol and 
xylene before coverslips were mounted (DPX mountant, BDH). 
 
Quantification was performed at x400 magnification (Leica DM RB microscope) using a 
previously described method that allows counting of positively stained cells/areas and 
requires no corrections based on other estimated quantities20; Openlab software (Improvision 
Openlab 4.0.2) was used for quantification.  All analysis was performed blinded as to group 
by the same assessor using a reference slide to check for consistency.  
 
Statistical analysis: All tests were performed using SPSS for Windows version 14.0.  
Summary data are presented as means ± SDs or median (interquartile range) as appropriate 
for their distribution.  Between group comparisons were made using 1-way ANOVA (with 
post hoc Gabriel’s test if significant)/Kruskal-Wallis tests or 2-tailed students t test/Mann-
Whitney U-tests depending on the distribution.  Correlations between the parameters were 
tested with either Pearson’s or Spearman’s Ranks correlation tests.  Discriminant function 
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analysis (DFA)21 using the method of Wilks was used to determine which of the markers 
studied allowed best discrimination between normal pregnancy and preeclampsia.  The null 
hypothesis was rejected where P < 0.05.   
 
Results 
Subjects: Table 3 describes the demographic, obstetric and pregnancy data of the 74 women 
who participated in the study.  All pregnancy groups conceived spontaneously and carried 
singleton pregnancies.  The normal pregnancy group gave birth without developing 
hypertension or proteinuria, to infants weighing > 2500 g, delivered 37 weeks or later.  The 
systolic and diastolic blood pressure levels were, by definition, significantly raised in 
preeclampsia compared to normal pregnancy (P < 0.0001).  Overall, the preeclamptic women 
all had moderate to severe disease and also had lower gestational ages at delivery than the 
control group (P < 0.0001) (Table 3). No preeclamptic woman had HELLP. All neonates 
from both pregnancy groups survived.   
 
Biochemical and molecular measurements: The values of plasma TBARS, serum selenium 
concentrations and plasma GPx activities are given in Table 4.  Maternal plasma TBARS 
levels were significantly higher in preeclampsia compared to both normal pregnancy and non-
pregnant controls (P < 0.001); no significant differences were observed between non-pregnant 
and normal pregnancy samples.  Umbilical venous TBARS concentrations were also 
significantly higher in preeclamptic than normal pregnancy (P = 0.04).   
 
There was a highly-significant trend for decreasing plasma selenium concentrations from non-
pregnant, to normal pregnant and pre-eclamptic women (Table 4; Kendall’s ; P<0.001).  
Selenium concentrations were also significantly reduced in umbilical venous samples in 
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preeclampsia by comparison with samples from babies of normotensive mothers (P < 0.0001).  
There was also a highly-significant trend for decreasing plasma GPx activity from non-
pregnant, to normal pregnant and pre-eclamptic women (Table 4; Kendall’s ; P<0.001). 
Umbilical venous plasma GPx activities were also significantly lower in preeclampsia than in 
normal pregnancy samples (P < 0.005).  There was a highly-significant overall correlation 
between maternal serum selenium concentrations with both maternal plasma and placental 
GPx activity (Figure 1a & b; r = 0.49; P < 0.001 and r = 0.38; P = 0.005 respectively), but no 
significant association within individual groups, or between umbilical venous serum selenium 
and GPx activity. 
 
No significant differences were observed in placental mRNA expression levels of GPx1, 3 
and 4 (P > 0.1) (Table 5).  As expected, no biologically significant placental GPx2 mRNA 
expression was observed.  Significantly lower activity of placental GPx activity was seen in 
preeclampsia compared to normal pregnancy placentae (P < 0.0001) (Table 5).  No significant 
differences in placental GPx activities were seen between sampling sites (P > 0.1), thus mean 
values are represented.  A significant negative correlation was observed between placental 
GPx activity and maternal TBARS concentrations in preeclampsia only (Figure 2).     
 
Due to the large spread of the corrected birthweight centiles in the preeclampsia group (Table 
3), we examined maternal GPx activity in mothers who gave birth to infants above and below 
the 50th centiles.  Univariate analysis of variance indicated that both pregnancy group and 
centile above/below 50th centile significantly react with maternal GPx activities (P < 0.001, P 
= 0.021 respectively) (Figure 3). 
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Immunohistochemistry:  Immunohistochemistry of GPx 1, 3 and 4 indicated positive 
expression in cytotrophoblast and Hofbauer cells (Figure 4).  Quantification revealed that the 
expression was significantly reduced in preeclampsia for all three GPx antibodies (GPx1 and 
GPx3: P < 0.05; GPx4: P < 0.001) (Figure 4). Location of positively stained areas was 
confirmed by staining with CK-7 and CD-68 antibodies (Figure 5).  No significant differences 
in expression were observed from the different placental sampling sites for any of the 
antibodies tested.  
 
Discriminant function analysis: Stepwise discriminant function analysis was applied to the 
whole sample using maternal serum selenium concentrations and plasma GPx activity 
produced a significant Wilks’ lambda test (assed using the F test)21 (Table 6) (P < 0.0001).  
DFA using these measurements correctly predicted 82% of the subjects, with correct 
classification of 84.6% of normal pregnancies and 78.3% of preeclamptic patients (Table 6). 
 
Discussion 
At present the source of the lipid peroxides in preeclampsia is unknown, but it has been 
suggested that poorly perfused placental tissue may evoke a free radical cascade and increase 
in generalised lipid peroxidation22.  By entering the maternal circulation, these lipid peroxides 
could affect the maternal endothelial cellular membranes by the increased production of ROS, 
thus contributing to the maternal vascular dysfunction10.  The significantly raised 
concentration of TBARS, a surrogate measure of lipid peroxidation, in the maternal 
circulation confirms previous reports10, 12. However, previous studies investigating oxidative 
stress have focussed on maternal parameters and only a single study appears to have been 
carried out in the fetus23. Our study also investigated umbilical venous concentrations of 
TBARS, which were significantly increased after preeclamptic pregnancy compared with 
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normal pregnancy, indicative of increased oxidative stress.  Defective placentation in 
preeclampsia could prevent the active placental transport of these lipid peroxides away from 
the fetus thus increasing the levels of TBARS in the umbilical venous samples.  This prenatal 
exposure to raised lipid peroxidation might be one of the factors predisposing the baby of the 
preeclamptic mother to cardiovascular disease in later life24, 25. 
 
Worryingly, the selenium concentrations in the non-pregnant women were lower than the 
recommended levels, as observed in other studies (eg26), suggesting that the selenium 
concentrations may not actually be high enough for optimum GPx activities even in the non-
pregnant population of the United Kingdom.  The selenium concentrations are further reduced 
in normal pregnancies (Table 4), illustrating a possible increased requirement for selenium 
during pregnancy.  However, this could also be due to inadequate absorption from the 
gastrointestinal tract, or inadequate renal reabsorption in the face of the increased glomerular 
filtration rate of pregnancy. Moreover this study also observed a further significant reduction 
in maternal selenium concentrations in the preeclamptic samples compared to both the normal 
pregnant and non-pregnant controls; this is in line with other studies10, 11 which measured  
serum selenium in samples with widely varying gestational ages and in toenail selenium 
concentrations respectively.  The lower selenium concentrations seen in preeclampsia might 
adversely affect the functional activities of the selenoproteins, GPx, thus compromising the 
protection against oxidative stress. Also, a recent report linked increased selenium intake over 
two years with significantly decreased excretion of the major thromboxane metabolite27. An 
early imbalance between thromboxane and prostacyclin synthesis has been implicated in the 
pathogenesis of preeclampsia over the last 20 years (eg28, 29). 
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The source of selenium to the fetus is via placental transport across a concentration gradient 
from the maternal circulation30. In the present study, selenium concentrations were 
significantly lower in the neonates of both groups, as compared to matched maternal serum; 
selenium is transported by simple diffusion across the placenta31. It is evident (Table 4) that 
the reduced selenium in the maternal circulation in preeclampsia is having a profound effect 
on the fetal selenium concentrations and thus could also compromise the mechanisms to 
protect the fetus from oxidative stress.   
 
The lower maternal and umbilical venous GPx activities observed in the preeclamptic samples 
indicates that insufficient antioxidant defence may be a contributing factor to the 
pathophysiological mechanisms associated with oxidative stress and preeclampsia.  However, 
it must be remembered that measured GPx activities should only be viewed in combination 
with other biomarkers, as its activity in plasma, unless organ specific, can be misleading.  
Nevertheless, our results provide information regarding a component of the global antioxidant 
defence levels in both the mother and baby.  The reduced plasma activities in the babies born 
to preeclamptic pregnancies in this study parallels the observation of reduced erythrocyte 
GPx12 and suggests that, as with the maternal samples, these babies may potentially have 
reduced antioxidant status.    
 
Small size at birth has been postulated to increase the risks of cardiovascular disease in later 
life24.  Maternal plasma GPx activity clearly differed by pregnancy outcome, in terms both of 
the presence or absence of preeclampsia, and whether the birthweight centile was above or 
below 50% (Figure 3). The higher plasma GPx in smaller babies was unexpected, but might 
reflect an adaptive response in these intrauterine growth restricted babies to try and protect 
these fetuses from oxidative stress. To our knowledge, this is a novel observation.  
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This is the first study to show the presence of three of the main forms of GPx in the human 
placenta.  Wang & Walsh, who did not differentiate the different GPxs, used Northern 
analysis and reported a significant decrease in expression in preeclampsia32. Whereas our real-
time PCR analysis and found no significant differences in any of the GPxs.  The 
immunohistochemical staining of all three GPx antibodies confirmed that as with the 
activities, the expression levels were significantly lower in the preeclamptic compared to 
normal placentae (Figure 4).  GPx in the cytotrophoblast cells is ideally located for the 
transportation of these GPxs into both the maternal and fetal circulations; these cells are 
exposed to relatively high oxygen concentrations and thus the GPxs may also protect the cells 
from oxidative stress33.  Due to the role of Hofbauer cells in vasculogenesis and angiogenesis, 
the GPxs may play essential roles in antioxidant protection throughout placental development 
and may indeed be the first line of antioxidant defence as these Hofbauer cells are found from 
week 4 of pregnancy until term34.   
 
Total placental GPx activities were also significantly lower in the preeclamptic placenta 
compared to normal pregnancy placentae, confirming previous studies13, 14.  This result 
therefore supports the hypothesis that in the placental compartment, at least, there is 
decreased GPx expression and activity contributing to the oxidative stress and enhanced 
biological oxidation in these tissues during preeclampsia.  The fact that no differences were 
found in placental GPx mRNA expression levels between pregnancy groups but the GPx 
activity was reduced in the preeclamptic placentae indicates a possible post-translational 
modification/mutation reducing the GPx antioxidant activity; this has been observed outside 
pregnancy35.  Moreover, the negative association seen between mean placental GPx activities 
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and maternal TBARS concentrations (Figure 2) in preeclampsia provides a further indication 
that the reduced placental antioxidant defence in the placenta could have functional effects. 
 
The GPxs are selenoproteins, but direct associations between the selenium concentrations and 
GPx activities have not previously been investigated with respect to preeclampsia.  The 
significant positive relationships seen in pregnancy per se (Figure 1a and b) suggest that at 
lower maternal selenium concentrations, there is a reduction in GPx; however as the selenium 
concentrations increases, the placental GPx activity begins to rise rapidly.  This is in line with 
the reports that the maternal Se concentrations must be clearly deficient to have a detrimental 
affect on GPx activities36 and this appears to be the case in some of the women suffering from 
preeclampsia in this study.  A possible hypothesis could be that the selenium concentrations 
may be below a threshold value for optimum GPx synthesis; this has been observed in studies 
of selenium deficiency in mice 37. 
 
Discriminant functional analysis using only maternal biochemical measurements (serum 
selenium concentrations and plasma GPx activities) classified 82% of the subjects into the 
correct pregnancy outcomes.   Caution must be exercised; this study was performed at the 
time of delivery, when the disease was established. Longitudinal studies are needed to 
determine whether similar differences antedate the onset of clinically-detectable disease, that 
is, whether they are cause or effect. If they do occur early, they would provide a novel 
addition to the analytes currently suggested as predictive.  
 
Perspectives 
These data are from this cross-sectional group of women with well characterised moderate-to-
severe preeclampsia.  The study illustrates how trace quantities of selenium can have very 
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significant physiological effects.  There is currently considerable interest in the role of dietary 
selenium supplementation as prophylaxis for various forms of cancer, such as prostate 
cancer38, another condition of aberrant vascular development. If selenium deficiency is 
confirmed in women suffering from preeclampsia, and continues to be linked with GPx 
inadequacy, consideration could be given to a randomised controlled trial of selenium 
supplementation in pregnancy. Furthermore, as assay methods become more readily available, 
measurements of serum selenium and GPx activity might contribute to the early identification 
of women at high risk of developing the disease.  Further longitudinal studies are required to 
elucidate a ‘cause or effect’ relationship for these factors. 
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Table Legends 
 
Table 1. Primers, sequences, product sizes and BLAST sequence numbers for the different 
glutathione peroxidases measured in this study.  
 
Table 2. Details of antibodies used. 
 
Table 3. Demographic and pregnancy data of subject groups. Data are presented as mean±SD 
or median [IQR] as appropriate, except for proteinuria: (median (min, max) and parity and 
Caesarean sections (number (percentage)).  †P < 0.05 between non-pregnant and both 
pregnancy groups; ‡P < 0.05 between normal and preeclamptic pregnancies.    
 
Table 4. Maternal and umbilical venous TBARS, selenium concentrations and GPx activities. 
Data are shown as mean±SD or median [IQR] as appropriate. ‡P < 0.0001 between non-
pregnant and both pregnancy groups; * P<0.005, **P < 0.0001 between normal and 
preeclamptic pregnancies. 
 
Table 5. Placental GPx mRNA expression and activities. Data are shown as (median (IQR)) 
as normalized ratios x1000. ‡P < 0.001 between normal and preeclamptic pregnancies. 
 
Table 6. Constant and discriminant function coefficients for the maternal predictors
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Figure Legends 
 
Figure 1. There were positive associations between maternal serum selenium concentrations 
with a) maternal plasma (r = 0.49; R2 = 0.24; P < 0.001) and b) placental (r = 0.38; R2 = 0.14; 
P = 0.005) GPx activities in pregnancy per se. 
 
Figure 2. Maternal TBARS concentrations and placental GPx activities were inversely 
correlated in the preeclamptic pregnant women (r = -0.54; R2 = 0.27; P = 0.008); no 
significant association was observed in the normal pregnancy samples. 
 
Figure 3. Maternal plasma GPx activity in normal and preeclamptic pregnancies split by baby 
birthweight centiles above and below the 50th centile. 
 
Figure 4. Immunohistochemical staining of GPx 1 (A1-A4), 3 (B1-B4) and 4 (C1-C4) 
placental sections from normal (A1, B1 & C1) and preeclamptic (A2, B2 & C2) pregnancies.  
(A3-A4; B3-B4; C3-C4 are positive and negative staining for each GPx).  Positive staining is 
shown in brown; black arrows indicate cytotrophoblast cells and white arrows show Hofbauer 
cells. x400 magnification. *P < 0.05 between normal and preeclamptic placentae.  
 
Figure 5. Representative placental sections of positive staining of CK-7 (A1) and CD68 (B1).  
Positive staining is shown in brown; black arrows indicate cytotrophoblast cells and white 
arrows show Hofbauer cells; negative controls are shown in A2 (cytotrophoblast cells) and B2 
(Hofbauer cells). x400 magnification.  
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Table 1. Primers, sequences, product sizes and BLAST sequence numbers. 
Primer Sequences (F=forward; R= reverse) BLAST Sequence No. 
GPx1 
F: CAACCAGTTTGGGCATCA    
R: CCGTTCACCTCGCACTTC NM_000581 
GPx2 
F: TGTGGCTTCGCTCTGAGG     
R: GTTCTCCTGATGTCCAAA NM_002083 
GPx3 
F: GATGGGAGGAGTACATCC    
R: ACCGAATGGTGCAAGCTC NM_002084 
GPx4 
F: GGCTACAACGTCAAATTCG   
R: GCAGGTCCTTCTCTATCA NM_002085 
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Table 2. Antibody details for immunohistochemistry  
Antigen Clone Titre (µg/ml) Positive control Supplier 
GPx1 (polyclonal) - 1:1000 dilution Thymus 
Autogen 
Bioclear, UK 
GPx3 (monoclonal) 23B1 1:100 dilution Prostate 
Autogen 
Bioclear, UK 
GPx4 (polyclonal) - 1:250 dilution Tongue 
Autogen 
Bioclear, UK 
Cytokeratin-7 (monoclonal) 
OV-TL 
12/30 0.5 - 
Santa Cruz 
Biotechnology 
CD-68 (monoclonal) PG-M1 1:50 dilution - 
Santa Cruz 
Biotechnology 
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Table 3. Demographic, pregnancy, clinical and biochemical data of subject groups 
Parameter* Non-pregnant 
Normal 
pregnant Preeclampsia  
Maternal age (years) 30±10.2 29±6.8 32±5.8 
Primipara (No. (%)) - 16(59.3) 17(68) 
Booking body mass index (Kg/m2) 22.7±4.8† 26.6±5.8 27.3±5.6 
Max. systolic blood pressure outside 
labour (mmHg) - 116±4.3 159±8.8‡ 
Max. diastolic blood pressure outside 
labour (mmHg) - 76±2.8 98±4.9‡ 
Proteinuria (g/L)  - - 1.0(0.3, 11.5) 
Gestation age at delivery (weeks) - 40±1.1 36.4±3.8‡ 
Caesarean section (No. (%)) - 4(15) 11(44)‡ 
Birthweight (Kg) - 3.55[3.25, 3.86] 2.92[1.92,3.51] ‡  
Birthweight centile  - 45[23, 67] 35[2, 87] 
Placental/birthweight ratio - 1.9±0.3 2.3 ± 1.1‡ 
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Table 4. Maternal and umbilical venous TBARS, selenium concentrations and GPx 
activities 
Biochemical measurement Non-pregnant Normal pregnant  Preeclampsia  
Maternal TBARS µmol/L 
(median[IQR]) 0.40[0.2, 0.7] 0.45[0.2, 0.8] 1.2[0.6, 1.6]‡ 
Umbilical venous TBARS µmol/L 
(median[IQR]) - 0.6[0.2, 0.8] 0.8[0.5, 1.0]‡ 
Maternal selenium µg/L (mean±SD) 68.8±2.5† 58.4±14.9 39.7±13.8‡ 
Umbilical venous selenium µg/L 
(mean±SD) - 42.1±11.8 29.0±9.9‡ 
Maternal plasma GPx activity 
nmol/min/ml (median[IQR]) 0.82[0.7, 0.9]‡ 0.53[0.4, 0.6] 0.32[0.1, 0.4]** 
Umbilical venous GPx activity 
nmol/min/ml (median[IQR]) - 0.51[0.4, 0.6] 0.39[0.2, 0.5]* 
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Table 5. Placental GPx mRNA expression and activities 
Placental GPx measurements Normal pregnant  Preeclampsia  
GPx1 normalized ratio mRNA expression 
(median([QR]) 5[1, 13] 4[2, 13] 
GPx3 normalized ratio mRNA expression 
(median[IQR]) 75[23, 116] 47[18, 91] 
GPx4 normalized ratio mRNA expression 
(median[IQR]) 5[2, 28] 12[3, 42] 
GPx activity nmol/min/mg (median[IQR]) 0.33[0.2, 0.6]   0.16[0.1, 0.2]‡ 
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Table 6. DFA data for maternal biochemical results   
Maternal predictive variable Coefficients 
Constant -4.06 
Serum Se concentrations (µg/L) 0.05 
Plasma GPx activity (nmole/min/L) 3.47 
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Figure 2.  
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Figure 3 
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Figure 4 
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Figure 5. 
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